Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates: clinical experience.

Robert E Coleman1

  • 1Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield, England S10 2SJ, United Kingdom. r.e.coleman@sheffield.ac.uk

The Oncologist
|October 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caffeic Acid, Reduced Glutathione, and Ferric Iron Addition Effects on the Redox Potential of Model Wine Solutions.

Molecules (Basel, Switzerland)·2026
Same author

Controlling the redox potential in red wines through cap management and mixing techniques.

Food chemistry·2025
Same author

Effect of Contrasting Redox Potential Evolutions and Cap Management Techniques on the Chemical Composition of Red Wine.

Molecules (Basel, Switzerland)·2025
Same author

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.

JAMA oncology·2024
Same author

Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.

Breast cancer research and treatment·2023
Same author

Chain Reaction of Fenton Autoxidation of Tartaric Acid: Critical Behavior at Low pH.

The journal of physical chemistry. B·2023
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Bisphosphonates are effective in preventing skeletal complications from bone metastases. Zoledronic acid shows the broadest efficacy across various cancer types, significantly reducing skeletal-related events and pain.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Bone metastases are a common complication of solid tumors, leading to significant skeletal morbidity.
  • Bisphosphonates are the standard treatment for preventing skeletal-related events (SREs) in patients with bone metastases.

Purpose of the Study:

  • To review the efficacy of bisphosphonates in managing skeletal complications of bone metastases.
  • To compare the effectiveness of different bisphosphonates, particularly zoledronic acid, across various cancer types.

Main Methods:

  • Review of clinical trial data evaluating bisphosphonate therapy for bone metastases.
  • Analysis of composite endpoints including skeletal-related events (pathologic fracture, spinal cord compression, surgery/radiation to bone, hypercalcemia of malignancy).

Main Results:

Related Experiment Videos

  • Bisphosphonates significantly reduce the incidence of SREs compared to placebo in breast cancer patients.
  • Zoledronic acid demonstrated superior efficacy over pamidronate in reducing SREs and provided sustained pain reduction in prostate cancer.
  • Zoledronic acid showed efficacy in bone metastases from lung cancer and renal cell carcinoma.

Conclusions:

  • Bisphosphonates are effective in reducing skeletal complications in patients with bone metastases.
  • Zoledronic acid exhibits the broadest clinical activity, demonstrating efficacy across a wide range of tumor types.